首页|NLR对PD-1抑制剂治疗HER2阴性晚期胃癌患者预后的预测价值分析

NLR对PD-1抑制剂治疗HER2阴性晚期胃癌患者预后的预测价值分析

扫码查看
目的 探索基线血清中性粒细胞/淋巴细胞(NLR)对细胞程序性死亡受体1(PD-1)抑制剂联合化疗治疗晚期胃癌患者的预后价值。方法 选取2018年1月至2021年1月秦皇岛市第四医院使用免疫联合化疗治疗方案的晚期胃癌患者168例为研究对象,随访截止时间为2023年1月。收集患者资料,联合初次治疗前血液学及肿瘤相关标志物进行分析,利用X-tile软件确定NLR的最佳截断值。采用Kaplan-Meier生存曲线分析NLR表达对晚期胃癌患者生存率的影响,受试者工作曲线(ROC)分析NLR对晚期胃癌患者预后的预测价值,结合Cox比例风险模型筛选影响晚期胃癌患者疾病进展的相关因素。结果 168例患者治疗前1周血清NLR的最佳截断值为2。41,将患者分为高NLR 组(NLR>2。41,n=93)和低 NLR 组(NLR≤2。41,n=75),NLR 水平与肿瘤分化、是否远处转移、细胞程序性死亡-配体1综合阳性评分、癌胚抗原、癌抗原125有关(P<0。05);低NLR组的免疫治疗联合化疗有效率明显高于高NLR组(P<0。05);低NLR组患者的中位无进展生存期(PES)和总生存期(OS)均较高NLR组延长(PFS:P=0。006;OS:P=0。023);ROC分析显示,NLR对晚期胃癌患者预后的曲线下面积为0。740,敏感度为81。50%,特异度为69。73%;在多变量分析中,除了治疗前NLR,肿瘤分化程度、是否远处转移也为晚期胃癌患者预后不良的独立预测因素(P<0。05)。结论 在接受免疫联合化疗的晚期胃癌患者中,治疗前NLR与疾病控制及PFS/OS具有相关性,对预测晚期胃癌免疫治疗预后有较高的价值。
Analysis of the prognostic value of NLR in the treatment of PD-1 inhibitors in patients with HER2-negative advanced gastric cancer
Objective To explore the prognostic value of serum neutrophils/lymphocytes(NLR)for first-line treatment of patients with advanced gastric cancer using programmed cell death receptor 1(PD-1)inhibitors.Methods A total of 168 patients with advanced gastric cancer who were treated with immunotherapy combined with chemotherapy in the Fourth Hospital of Qinhuangdao from January 2018 to January 2021 were selected as study subjects,and the follow-up period was terminated at January 2023.The patients'data were collected,hematological and tumor markers before the combined treatment were analyzed,and the optimal cut-off value of NLR was calculated using X-tile software.The effect of NLR expression on the survival rate of patients with advanced gastric cancer was analysed by the Kaplan-Meier survival curve.Receiver operating curve(ROC)was used to analyze the predictive value of NLR in patients with advanced gastric cancer.The related factors affecting the disease progression of patients with advanced gastric cancer were screened combined with Cox proportional risk model.Results Among 168 patients,the optimal cut-off value of serum NLR before treatment was 2.41.Patients were divided into high NLR group(NLR>2.41,n=93)and low NLR group(NLR<2.41,n=75).NLR was related to tumor differentiation,distant metastasis,composite positive scores of PD-L1,carcinoembryonic antigen and cancer antigen 125(P<0.05);the effective rate in the low NLR group was significantly higher than that in the high NLR group(P<0.05);the median progression free survival(PFS)and the overall survival(OS)of patients in the low NLR group were both longer than those in the high NLR group(PFS:P=0.006;OS:P=0.023);ROC analysis showed that the area under the curve of NLR for the prognosis of advanced gastric cancer patients was 0.740,sensitivity was 81.50%,and specificity was 69.70%;in multivariate analysis,except initial NLR value,tumor differentiation degree and distant metastasis were also independent predictors of poor prognosis in patients with advanced gastric cancer(P<0.05).Conclusion Among patients with advanced gastric cancer who received first-line immunotherapy combined with chemotherapy,pretreatment NLR is correlated with efficacy and PFS/OS,and has high value in predicting the prognosis of immunotherapy for advanced gastric cancer.

Advanced gastric cancerImmunotherapyNeutrophils/lymphocytesPrognosisChemotherapyhuman Epdermal growth factor receptor

窦雅琳、成伟丽、孙明琪、武双红、杨婷婷、李大鹏

展开 >

秦皇岛市第四医院肿瘤内科(河北秦皇岛 066000)

秦皇岛市第四医院急诊科(河北秦皇岛 066000)

晚期胃癌 免疫治疗 中性粒细胞/淋巴细胞比值 预后 化学疗法 表皮生长因子受体-2

秦皇岛市科学技术研究与发展计划项目

202301A153

2024

中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
年,卷(期):2024.27(6)